Table 1.
Characteristics of trials discontinuing TKI.
| Author | N | Minimum TKI Duration (y) | Type of TKI | Minimum DMR Duration (y) | Median Follow Up (m) | The Median Time to MR (m) | TFR Rate | Treatment Reinitiation |
|---|---|---|---|---|---|---|---|---|
| STIM [35,36] | 100 | 3 | IM | UMRD ≥ 2 | 77 | 2.5 | 43% at 24 months and 38% at 60 months. | Loss of UMRD |
| TWISTER [37] | 40 | 3 | IM | UMRD ≥ 2 | 43 | 3 | 47.1% at 24 months. | Loss of UMRD |
| ASTIM [38] | 80 | 3 | IM | MR4 ≥ 2 | 31 | 4 | 64% at 24 months and 61% at 36 months. | Loss of MMR, UMRD |
| HOVON [31] | 15 | 2 | IM | MR4.5 > 2 | 36 | 3 | 33% at 24 months. | Loss of MR4.5 |
| ISAV [39] | 108 | 2 | IM | UMRD ≥ 1 | 21.6 | NR | 48% at 36 months. | Loss of MMR |
| KID [40] | 90 | 2 | IM | MR4.5 > 2 | 26.6 | 3.3 | 62.2% at 12 months and 58.5% at 24 months. |
Loss of MMR |
| EURO-SKI [34] | 755 | 3 | IM & NL & DA | MR4 ≥ 1 | 27 | 6 | 61% at 6 months and 50% at 24 months. | Loss of MRR |
| DADI (2015) [41] | 63 | 1 | DA | DMR ≥ 2 | 20 | 3 | 49% at six months and 48% at 12 months. | Loss of MR4 |
| DADI (2020) [42] | 58 | 3 | DA | DMR ≥ 2 | 23.3 | 2 | 55% at 6 months. | Loss of MR4 |
| ENESTfreedom [43] | 190 | 3 | NL | MR4.5 ≥ 2 | 12 | NR | 51.6 at 48 weeks. | Loss of MMR |
| Ho-Young Yhim [44] | 14 | 2 | IM | DMR ≥ 2 | 23 | NR | 28.6% at 12 months. | Loss of MMR |
| GIMEMA [45] | 293 | 7 | IM, NL, DA, BO | DMR ≥ 3 | 34 | 3–4 | 69% at 12 months and 62% at 34 months. | Loss of MMR |
| STIM2 [46] | 124 | 3 | IM | DMR ≥ 2 | 12 | 6 | 61.2% at 12 months. | Loss of MMR |
| Kieo STIM [47] | 40 | 2 | IM | DMR ≥ 2 | 15.5 | NR | 55.4% at 12 months. | Loss of MMR |
| Pagnano KB [48] | 48 | 3 | IM | DMR ≥ 2 | NR | NR | 61% at 20 months. | Loss of MMR |
| TRAD [49] | 67 | 3 | IM | MR4.5 ≥ 2 | NR | NR | 64.7% at 6 months. | Loss of MMR |
| STIM231 [50] | 68 | 3 | IM | MR4 ≥ 2 | NR | NR | 67.6% at 12 months and 65% at 36 months. | Loss of MMR |
| STOP2G [51] | 60 | 3 | NL, DA | MR4.5 ≥ 2 | 47 | 4 | 63.3% at 12 months and 53.7% at 48 months. |
Loss of MMR |
| D-STOP [52] | 54 | 2 | DA | DMR ≥ 2 | 16 | NR | 62.9% at 1 year. | Loss of MMR |
| DASFREE [53] | 84 | 2 | DA | MR4.5 ≥ 1 | NR | 5 | 48% at 12 months and 46% at 24 months. | Loss of MMR |
| STATS [54] | 78 | 2 | NL | MR4.5 ≥ 2 | 35.4 | 6 | 67.9% at 12 months and 62.8% at 24 months. |
Loss of MR4.5 |
| DOMEST [55] | 99 | 2 | IM | MR4 ≥ 2 | 12 | NR | 70% at 6 months, 68% at 12 months, and 64% at 24 months. |
Loss of MR4 |
Abbreviations: IM = Imatinib, DA = Dasatinib, NL = Nilotinib, B = Bosutinib, MR = molecular response, DMR = deep molecular response, TKI = tyrosine kinase inhibitor, MMR = major molecular response, TFR = treatment-free remission, UMRD = undetected minimum residual disease, and NR = not reported.